{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:36:22Z","timestamp":1792236982113,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1124\/dmd.117.075226","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:25:49Z","timestamp":1492734349000},"page":"712-720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s"],"prefix":"10.1016","volume":"45","author":[{"given":"Zhican","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli","family":"Teague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansen","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Morisseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Hammock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan A.","family":"Rock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.117.075226_bib1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.leu.2402417","article-title":"The proteasome: a novel target for cancer chemotherapy","volume":"16","author":"Almond","year":"2002","journal-title":"Leukemia"},{"issue":"Suppl 5","key":"10.1124\/dmd.117.075226_bib2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.6004\/jnccn.2013.0199","article-title":"Therapeutic advances in relapsed or refractory multiple myeloma","volume":"11","author":"Anderson","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1124\/dmd.117.075226_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1081\/DMR-100101908","article-title":"Kinetic and chemical mechanism of epoxide hydrolase","volume":"31","author":"Armstrong","year":"1999","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.117.075226_bib4","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","article-title":"Approval summary for bortezomib for injection in the treatment of multiple myeloma","volume":"10","author":"Bross","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.117.075226_bib5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/1535-7163.MCT-04-0338","article-title":"Proteasome inhibitor therapy in multiple myeloma","volume":"4","author":"Chauhan","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.117.075226_bib6","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1002\/anie.200501428","article-title":"Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture)","volume":"44","author":"Ciechanover","year":"2005","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1124\/dmd.117.075226_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1023\/A:1012414806166","article-title":"Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours","volume":"33","author":"Coller","year":"2001","journal-title":"Histochem J"},{"key":"10.1124\/dmd.117.075226_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00204-009-0416-0","article-title":"Mammalian epoxide hydrolases in xenobiotic metabolism and signalling","volume":"83","author":"Decker","year":"2009","journal-title":"Arch Toxicol"},{"key":"10.1124\/dmd.117.075226_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1124\/dmd.117.075226_bib10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system","volume":"14","author":"Dou","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1124\/dmd.117.075226_bib11","unstructured":"Fang Y, Wang Z, Zhang T, Teague J, and Wang Z (2015) Contribution of epoxide hydrolase and cytochrome P450 (CYP) enzymes on oprozomib disposition. AAPS 2015-001707."},{"key":"10.1124\/dmd.117.075226_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-2797(00)00197-6","article-title":"Epoxide hydrolases: biochemistry and molecular biology","volume":"129","author":"Fretland","year":"2000","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.117.075226_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0006-2952(80)90518-3","article-title":"Distribution and properties of a mammalian soluble epoxide hydrase","volume":"29","author":"Gill","year":"1980","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.117.075226_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00063030-200519030-00003","article-title":"Oral delivery of peptide drugs: barriers and developments","volume":"19","author":"Hamman","year":"2005","journal-title":"BioDrugs"},{"key":"10.1124\/dmd.117.075226_bib15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.str.2014.11.017","article-title":"Crystal structure of the human 20S proteasome in complex with carfilzomib","volume":"23","author":"Harshbarger","year":"2015","journal-title":"Structure"},{"key":"10.1124\/dmd.117.075226_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/abbi.1996.9794","article-title":"Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression","volume":"337","author":"Hassett","year":"1997","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.117.075226_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cbi.2004.07.004","article-title":"Functional analysis of human microsomal epoxide hydrolase genetic variants","volume":"150","author":"Hosagrahara","year":"2004","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.117.075226_bib18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s10637-016-0327-x","article-title":"A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors","volume":"34","author":"Infante","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1124\/dmd.117.075226_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","article-title":"Proteasome inhibitors: from research tools to drug candidates","volume":"8","author":"Kisselev","year":"2001","journal-title":"Chem Biol"},{"key":"10.1124\/dmd.117.075226_bib20","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-3565(25)20748-0","article-title":"Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene","volume":"278","author":"Kitteringham","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.075226_bib21","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/dmd.115.063339","article-title":"The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain","volume":"43","author":"Kodani","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075226_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/clpt.1993.180","article-title":"In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide","volume":"54","author":"Kroetz","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.075226_bib23","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1124\/dmd.117.075226_bib24","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.117.075226_bib25","first-page":"49","article-title":"Membrane proteins which exhibit multiple topological orientations","volume":"31","author":"Levy","year":"1996","journal-title":"Essays Biochem"},{"key":"10.1124\/dmd.117.075226_bib26","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1073\/pnas.070047997","article-title":"Bax degradation by the ubiquitin\/proteasome-dependent pathway: involvement in tumor survival and progression","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.117.075226_bib27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm0297-231","article-title":"Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas","volume":"3","author":"Loda","year":"1997","journal-title":"Nat Med"},{"key":"10.1124\/dmd.117.075226_bib28","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.117.075226_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/abbi.2000.1810","article-title":"Cress and potato soluble epoxide hydrolases: purification, biochemical characterization, and comparison to mammalian enzymes","volume":"378","author":"Morisseau","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.117.075226_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ab.2011.02.038","article-title":"Development of fluorescent substrates for microsomal epoxide hydrolase and application to inhibition studies","volume":"414","author":"Morisseau","year":"2011","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.117.075226_bib31","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1021\/tx700446u","article-title":"Development of metabolically stable inhibitors of Mammalian microsomal epoxide hydrolase","volume":"21","author":"Morisseau","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.117.075226_bib32","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.117.075226_bib33","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075226_bib34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/BF00332483","article-title":"Cytosolic epoxide hydrolase in humans: development and tissue distribution","volume":"62","author":"Pacifici","year":"1988","journal-title":"Arch Toxicol"},{"key":"10.1124\/dmd.117.075226_bib35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3892\/mmr_00000324","article-title":"Microsomal epoxide hydrolase polymorphisms","volume":"3","author":"Pinarbasi","year":"2010","journal-title":"Mol Med Rep"},{"key":"10.1124\/dmd.117.075226_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2015.07.569","article-title":"Oprozomib (OPZ) and dexamethasone (DEX) in patients (PTs) with relapsed and\/or refractory multiple myeloma (RRMM): Updated results from dose escalation in a phase 1b\/2, multicenter, open-label study","volume":"15","author":"Prada","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1124\/dmd.117.075226_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.53","article-title":"New investigational drugs with single-agent activity in multiple myeloma","volume":"6","author":"Rajan","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1124\/dmd.117.075226_bib38","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1021\/jm100691c","article-title":"1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain","volume":"53","author":"Rose","year":"2010","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.117.075226_bib39","article-title":"Oprozomib, pomalidomide, and dexamethasone (OPomd) in patients (Pts) with relapsed and\/or refractory multiple myeloma (RRMM): initial results of a phase 1b study","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"key":"10.1124\/dmd.117.075226_bib48","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/00498250500183132","article-title":"Impaired glutathione-conjugating capacity by cryopreserved human and rat hepatocytes","volume":"35","author":"Sohlenius-Sternbeck","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.117.075226_bib40","unstructured":"Teague J, Wang Z, Jones J, Jiang J, Muchamuel T, Phizackerley K, Wong H, and Kirk C (2013) Understanding the absorption characteristics of the oral (PO) proteasome inhibitor oprozomib in the gastrointestinal (GI) tract. AAPS 2013-000358."},{"key":"10.1124\/dmd.117.075226_bib41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1345\/aph.1R561","article-title":"Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma","volume":"47","author":"Thompson","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1124\/dmd.117.075226_bib49","article-title":"A phase I study of oprozomib to assess drug-drug interaction with midazolam in patients with advanced malignancies","volume":"99","author":"Tsimberidou","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.075226_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2015.07.071","article-title":"Microsomal epoxide hydrolase 1 (EPHX1): Gene, structure, function, and role in human disease","volume":"571","author":"V\u00e1clav\u00edkov\u00e1","year":"2015","journal-title":"Gene"},{"key":"10.1124\/dmd.117.075226_bib43","article-title":"Updated results from a multicenter, open-label, dose-escalation phase 1b\/2 study of single-agent oprozomib (OPZ) in patients (PTs) with hematologic malignancies, including multiple myeloma (MM)","volume":"100","author":"Vij","year":"2015","journal-title":"Haematologica"},{"key":"10.1124\/dmd.117.075226_bib44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.112.047662","article-title":"Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib","volume":"41","author":"Wang","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075226_bib45","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrd1851","article-title":"Predicting in vivo drug interactions from in vitro drug discovery data","volume":"4","author":"Wienkers","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.117.075226_bib46","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.111.039164","article-title":"Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats","volume":"39","author":"Yang","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075226_bib47","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J Med Chem"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624053728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624053728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.117.075226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:22:46Z","timestamp":1739902966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624053728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0090955624053728"],"URL":"https:\/\/doi.org\/10.1124\/dmd.117.075226","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.117.075226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}